Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ResMed Inc. (RMD) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ResMed’s common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol RMD, and its filings offer detailed insight into governance, compensation, capital returns, and financial performance.
Among the key documents available are Form 8-K current reports, where ResMed discloses material events. Recent 8-K filings describe quarterly and annual results of operations, dividend declarations, and changes in the composition of the board of directors. They also cover amendments to equity-based incentive plans and the employee stock purchase plan, including increases in reserved shares and changes to plan terms approved by stockholders at the annual meeting.
Investors can also review the company’s Definitive Proxy Statement on Schedule 14A, which discusses board structure, director elections, executive compensation, and long-term strategic priorities. The proxy materials outline ResMed’s mission around sleep and breathing health, its 2030 goals, and its approach to aligning incentive programs with performance and shareholder interests.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex sections, such as compensation plans, dividend announcements, and voting results from the annual meeting. Users can quickly see what the board has approved, how stockholders voted on proposals, and how ResMed’s capital management policies, including recurring cash dividends, are documented in its official records.
Because Form 8-K reports and proxy statements are updated over time, the filings page offers a chronological view of ResMed’s regulatory history, from financial disclosures to governance changes. This makes it a useful resource for investors who want to understand how the company reports its performance, manages equity plans, and communicates significant events through the SEC’s EDGAR system.
ResMed Inc. Chief Executive Officer Michael J. Farrell reported the vesting and receipt of performance-based restricted stock units. On 08/15/2025, 12,289 shares of ResMed common stock were acquired at a $0 price because they were earned under a performance-based restricted stock unit award granted 11/20/2024 after the compensation committee certified that performance metrics were met. After the transaction, Farrell beneficially owned 467,792 shares directly and held an indirect interest in 2,090 shares through the Lisette and Michael Farrell Family Trust. The award vests one-third each year on the grant anniversary.
ResMed Inc. (RMD) director John Hernandez exercised stock options and sold the resulting shares on 08/18/2025. He executed option exercises totaling 2,575 shares at an exercise price of $148.90 per share and concurrently sold 2,575 shares at a weighted average sale price of $287.1026. Following these transactions his beneficial ownership decreased from 6,620 shares to 4,045. The filing notes options became exercisable on 11/11/2024 (with vesting rules) and that the sale price range was $286.90–$287.24.
Insider acquisition of ResMed common stock via vested performance awards. Michael J. Rider, Global General Counsel and Secretary of ResMed Inc. (RMD), reported that 2,941 shares of ResMed common stock were acquired on 08/15/2025 at a $0 price as the result of performance-based restricted stock units granted on 11/20/2024 that vested when the compensation committee certified performance metrics were met. After the transaction, Rider beneficially owns 11,427 shares. The filing indicates the award vests in one-third increments annually on the grant anniversary; no cash purchase occurred. This Form 4 was signed on 08/19/2025.
ResMed Inc. has appointed Nicole Mowad-Nassar to its board of directors, effective immediately, with her initial term running until the November 19, 2025 annual meeting, unless it ends earlier. She serves as senior vice president and president of specialty and U.S. therapeutics operations at AbbVie Inc.
Mowad-Nassar will join ResMed’s Compensation and Leadership Development Committee and receive non-executive director compensation under the company’s standard director program, including a cash retainer of $75,000 for fiscal 2026. ResMed will also enter into its customary indemnification agreement with her.
Director Richard Sulpizio has informed the company that he will not stand for re-election and intends to retire from the board at the 2025 annual meeting, anticipated on November 19, 2025. His decision is stated not to result from any disagreement with ResMed’s operations, policies, or practices.
ResMed (RMD) Form 144 notice: An insider intends to sell 2,575 shares of ResMed common stock on the NYSE through Fidelity Brokerage Services. The filing lists an aggregate market value of $739,289.14 and shows 146,414,839 shares outstanding. The securities were reported as acquired in connection with an option granted on 11/16/2023 and listed as acquired and scheduled for sale on 08/18/2025. The transaction is shown as a cash sale through the named broker. The filer states they are not aware of undisclosed material adverse information about the issuer.
ResMed Chief Executive Officer Michael J. Farrell exercised stock options and sold shares on 08/07/2025 under a Rule 10b5-1 plan adopted on October 31, 2024. He exercised 8,009 options at a $101.64 exercise price, acquiring 8,009 common shares, and sold those 8,009 shares in multiple trades at a weighted-average price of $279.4829 (individual trades ranged $277.76–$282.66). After the transactions Farrell’s direct beneficial ownership is reported as 455,503 shares, and he also holds 24,029 derivative securities; 2,090 shares are held indirectly via the Lisette and Michael Farrell Family Trust.
Filing: Form 4 filed by Brett Sandercock, Chief Financial Officer of ResMed Inc. (RMD), signed 08/04/2025.
On 08/01/2025 Mr. Sandercock reported two non-derivative transactions and one derivative entry. He acquired 2,000 shares of ResMed common stock under a Rule 10b5-1 plan at $101.64 (reported beneficial ownership after this line: 86,283 shares). He disposed of 3,000 shares at $281.90 (reported beneficial ownership after this line: 83,283 shares). Separately, he reported 2,000 option-related derivative securities with an exercise price of $101.64, exercisable from 11/11/2019 and expiring 11/14/2025, leaving 6,000 derivative securities beneficially owned following the report.
Disclosures: The stock transactions were executed under a Rule 10b5-1 plan adopted February 19, 2025. Options vest 1/3 per year.
ResMed Inc. (RMD) Form 4: Global General Counsel & Secretary Michael J. Rider reported a modest open-market sale of company stock.
- Transaction: On 01 Aug 2025 he sold 50 common shares at $281.90 each, generating roughly $14.1k in gross proceeds. The sale was carried out under a pre-arranged Rule 10b5-1 plan adopted 28 Feb 2025.
- Post-sale holdings: Rider now directly owns 8,486 shares; no derivative positions were reported.
The divestiture represents an immaterial decrease in the executive’s stake and an insignificant fraction of ResMed’s total float, suggesting limited market impact. Because the trade was executed under a 10b5-1 plan, timing-related information asymmetry concerns are mitigated. Investors may view the filing as routine but should track subsequent insider activity for trend changes.